A DNA Hypomethylation Signature Predicts Novel Anti-Tumor Activity of LSD1 Inhibitors in SCLC
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 136 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- Small cell lung cancerThis series is part of our curated briefing on it.
- Samples
- 136 samples
- Data you can get
- A processed expression table (series matrix) and the array files, from NCBI.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE66298_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA276451 and SRA study SRP055507. Searching any of these in the dataset finder brings you back here.
The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.
+ 136 more — browse all 136 samples with per-sample file links →
- GSE272002 LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC 324 samples same disease briefing · shares lsd1, sclc
- GSE280643 Differential KEAP1/NRF2-mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy 74 samples same disease briefing · shares sclc
- GSE279100 Differential KEAP1/NRF2-mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy [seq] 50 samples same disease briefing · shares sclc
- GSE149507 Microarray expression data of 18 pairs of small cell lung cancer (sclc) and tumor and adjacent lung tissues 36 samples same disease briefing · shares sclc
- GSE64766 Selective Loss of RB in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to SCLC 16 samples same disease briefing · shares sclc
- GSE267928 Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC 12 samples same disease briefing · shares sclc
- GSE245123 A key netwrok hub gene GRN confers chemo resistance in H2081 SCLC cells. 6 samples same disease briefing · shares sclc
- GSE303152 Neuronal-Activity Dependent Mechanisms of Small Cell Lung Cancer Pathogenesis 36 samples same disease briefing · shares activity
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.